Key Takeaways
- Volume-led 13.6% revenue growth: A strong monsoon and higher crop sowing drove volumes, but Chinese dumping crushed technical prices ~19-20%, muting the top-line benefit.
- Margins rebounded on efficiency, not price: EBITDA margin hit 16.6-17%, lifted by process optimization, zero inventory write-downs, and stable raw material costs, not by any pricing power.
- Hamirpur is the multi-year growth engine: The first block commissions in Q1 FY26, targeting ₹50-60 crores in FY26 revenue, with a long-term path to ₹700-800 crores from up to 11 blocks.
- Formulation is the nearer-term volume story: Formulation volumes jumped ~40%, and management targets at least 20% annual growth by adding products and expanding beyond its current 15-state footprint.
- What to watch next quarter: Whether the European insecticide approval converts to orders, the Japanese tie-up yields firm volume commitments, and if H2 EBITDA margins actually reach the guided 18-20% band.
China-Led Pricing Pressure & Volume Strategy
- Technical prices crushed by dumping: Blended technical prices fell ~19-20% YoY as Chinese competitors dumped material at what management calls unreasonable prices, forcing a volume-over-price strategy that kept technical revenue flat at ~₹131 crores despite ~30% volume growth.
- Raw material relief is a partial offset: Raw material costs declined in a similar range to finished goods prices, and both have stabilized by end-Q2, so the gross margin damage is contained but not reversed.
- Captan and Folpet holding ground: Prices for these core products declined ~15%, but raw material costs fell similarly, and Folpet production is running at planned capacity with no significant new Chinese entrants visible yet.
- Export demand is structurally subdued: Management flagged that international market demand has declined amid excess supply from some countries, compressing gross profit margins across the industry.
D.K. Jain: "Pricing pressure from China still continues because they are trying to dump the material as much as possible at unreasonable prices. But we are also well equipped now to take on the Chinese competition."
Hamirpur: The Multi-Year Capacity Build
- First revenue in FY26: The first block is in an advanced stage of completion with equipment ordered and some already on site; it commissions in Q1 FY26, with the second block following in Q2, together targeting ₹50-60 crores of revenue next year.
- Long-term ambition is ₹700-800 crores: Management sees scope for 10-11 blocks built at a pace of two per year, with total investment of another ₹200-300 crores over time, and additional land available in the industrial area if needed.
- Blocks are fungible: While each block is designed for a particular product, they can be switched to another molecule if demand shifts, and existing environmental clearance covers products already in the submitted list without needing fresh approvals.
- Registration pipeline is filling: One product for Hamirpur has already received registration, and another product for export has also been registered, de-risking the initial ramp.
D.K. Jain: "Ultimately, we would be spending another Rs.200 crores - Rs.300 crores in our Hamirpur facility, because we will be building this facility block by block... we feel that there is a scope of adding almost 10, 11 blocks."
Formulation: The Domestic Growth Bet
- Volumes surged ~40%: Formulation revenue saw a significant jump in H1, driven by a 40% volume increase as the company added products and deepened its presence across 15 states.
- At least 20% annual growth targeted: Management expects to outpace the ~9-10% overall Indian agrochemical consumption growth by expanding its geographic footprint to more states and continuously adding products to the portfolio.
- Sandila formulation capacity expanding: Current formulation capacity of ~3,000 tonnes at Sandila is being expanded by ~2,000 tonnes this year, funded within the ₹110 crore FY25 capex envelope.
- Margin profile is slightly lower: Formulation carries slightly less gross margin than technicals, so the mix shift toward formulations will be a modest structural drag on blended margins even as it drives revenue growth.
D.K. Jain: "Formulation growth also would be similar, at least 20% per year. And India has been growing almost 9% to 10% per year overall consumption... we plan to have more than 20% increase every year."
Margin Recovery: Efficiency, Not Pricing
- EBITDA margin climbed to 16.6-17%: The improvement from the year-ago quarter came from three levers: no inventory write-downs (last year had a sharp raw material price decline that caused losses), better scale of operations, and R&D-driven yield improvements in technical products.
- Process optimization is the next leg: Management expressed confidence in reaching 18-20% EBITDA margin in H2, citing R&D work on process optimization that has already delivered success this quarter, with more expected in the coming quarter, assuming raw material prices hold steady.
- Gross margin sustainability is conditional: If raw material prices remain at current levels, gross margins should stay in a similar range, but the export pricing environment remains subdued and is an industry-wide headwind.
D.K. Jain: "We are focusing now on our process optimization. And that work our R&D team is doing continuously day in and day out, and we have achieved some success during this quarter."
Regulatory & Customer Access Wins
- European technical equivalence secured: A niche insecticide already produced for domestic consumption received technical equivalence in Europe; customers now need 2-3 months to obtain their own permissions before purchases can begin, so revenue conversion is a Q4 FY25 or Q1 FY26 event.
- Japanese tie-up signed, volumes pending: An agreement is in place with a large Japanese company that will buy product from IPL; a meeting is scheduled this month, with the customer expected to begin sourcing in January/February, but volumes and pricing are not yet negotiated.
- Intermediate plant commissioned: A new intermediate plant for backward integration of one core fungicide, developed with indigenous R&D, is now operational, reducing import reliance and supporting gross margins on that molecule.
D.K. Jain: "That company is a very big company, we expect good volumes and good products from them in the coming future."
Inventory & Working Capital
- Inventory days rose to ~150: The build was deliberate: the company stocked herbicide technicals for the next Kharif season, and the product mix shift toward seasonal domestic formulations with short selling windows structurally requires higher inventory than the historical export-heavy technical business.
- Target is 120-130 days by March: Management expects inventory days to normalize as seasonal stocks are drawn down, though the new product mix means the pre-COVID norm of lower inventory days is no longer the right baseline.
- Capex back-end loaded: Only ₹15 crores of the ₹110 crore FY25 plan was spent through September; the bulk will hit in H2 as equipment reaches the Hamirpur and Sandila sites.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Hamirpur first revenue | First block commissioned, targeting ₹50-60 crores combined from two blocks | Q1 FY26 (block 1), Q2 FY26 (block 2) |
| Hamirpur long-term capacity | ₹700-800 crores revenue from up to 10-11 blocks, built at ~2 blocks/year | 3-4 years |
| Existing plant revenue growth | 15-20% increase from existing plants | FY26 |
| Formulation growth | At least 20% per year | Ongoing annual target |
| H2 EBITDA margin | 18-20%, contingent on stable raw material prices | H2 FY25 |
| FY25 capex | ₹110 crores (IPL + SSL combined), funded internally | FY25 |
| Inventory days normalization | 120-130 days | By March 2025 |
| European insecticide sales | Revenue conversion after customers obtain permissions (2-3 months) | Q4 FY25 / Q1 FY26 |
| Japanese customer onboarding | First purchases expected | January/February 2025 |
| Sandila formulation expansion | ~2,000 tonnes added to existing ~3,000 tonnes | FY25 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹234 crores, +13.6% YoY and +4.5% QoQ |
| EBITDA | ₹39 crores, +25.2% YoY; EBITDA margin at 16.6% |
| Net profit | ₹26 crores, +32.9% YoY |
| Domestic revenue | ₹155 crores |
| Export revenue | ₹74 crores |
| Technical sales | ₹131 crores, flat YoY (₹139 crores in Q2 FY24) |
| Formulations sales | ₹98 crores |
| Technical volume growth | ~30% YoY |
| Blended price decline | ~19% to 20% YoY |
| H1 FY25 revenue | ₹458 crores, +11% YoY |
| H1 FY25 EBITDA | ₹71 crores, vs ₹57 crores in H1 FY24 |
| Cash and cash equivalents | ₹127 crores at quarter-end |
| FY25 capex target | ₹110 crores (₹50 crores Sandila, ₹60 crores Hamirpur) |
| Inventory days | ~150 days, expected to normalize to 120–130 days by March |
| Sandila capacity utilization | ~60% to 65% |